| Chapter title |
The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy
|
|---|---|
| Chapter number | 8 |
| Book title |
Exercise for Cardiovascular Disease Prevention and Treatment
|
| Published in |
Advances in experimental medicine and biology, January 2017
|
| DOI | 10.1007/978-981-10-4304-8_8 |
| Pubmed ID | |
| Book ISBNs |
978-9-81-104303-1, 978-9-81-104304-8
|
| Authors |
Cavarretta Elena, Mastroiacovo Giorgio, Lupieri Annik, Frati Giacomo, Peruzzi Mariangela, Elena Cavarretta, Giorgio Mastroiacovo, Annik Lupieri, Giacomo Frati, Mariangela Peruzzi, Cavarretta, Elena, Mastroiacovo, Giorgio, Lupieri, Annik, Frati, Giacomo, Peruzzi, Mariangela |
| Abstract |
Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin, are powerful chemotherapeutic drugs used both in children and adult populations. Their properties made them particularly suitable for a large variety of neoplasms including breast adenocarcinoma, small cell lung cancer and acute leukemia. Early and late anthracycline-induced cardiotoxicity is a well-known phenomenon, and the incidence of heart failure in patients receiving doxorubicin is 2.2%, with a mortality rate over 60% at 2 years. Prognosis can be improved by prevention, early detection and treatment. A specific treatment for anthracycline-induced cardiotoxicity is not yet available, but non-pharmacological measures such as exercise, lifestyle changes and control of risk factors have shown a cardioprotective effect. Exercise training represents a viable non-pharmacological treatment as it increases cardiovascular reserve and endothelial function, regulates proapoptotic signaling, protects against reactive oxygen species (ROS), and decreases autophagy/lysosomal signaling. However, no current guidelines are available for prevention management in cancer patients. Pharmacological measures both for prevention and treatment are those used for heart failure (β-blockers, angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, statins, dexrazoxane and aldosteron antagonists). In this chapter, we will discuss how the evaluation, monitoring and prevention of chemotherapy-related cardiomyopathy is correlated with physical exercise. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 25% |
| Australia | 1 | 6% |
| Sweden | 1 | 6% |
| France | 1 | 6% |
| Greece | 1 | 6% |
| Unknown | 8 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 63% |
| Scientists | 5 | 31% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 148 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 27 | 18% |
| Student > Bachelor | 19 | 13% |
| Researcher | 9 | 6% |
| Student > Ph. D. Student | 9 | 6% |
| Student > Doctoral Student | 8 | 5% |
| Other | 24 | 16% |
| Unknown | 52 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 23% |
| Nursing and Health Professions | 14 | 9% |
| Sports and Recreations | 12 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 20 | 14% |
| Unknown | 59 | 40% |